The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.
 
Kai He
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Geneplus; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Perthera
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech/Roche; GlaxoSmithKline; Intellisphere; InThought; Iovance Biotherapeutics; Janssen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Merck KGaA; Mirati Therapeutics; MSD Oncology; NCCN/AstraZeneca; Novartis; OncLive/MJH Life Sciences; Pfizer; PPD; Regeneron; Roche; Sanofi
 
Meredith McKean
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Castle Biosciences (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Accutar Biotech (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); OncoC4 (Inst); Oncorus (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Takeda (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Rama Balaraman
Employment - Ocala Oncology Florida Cancer Affiliates
Leadership - Ocala Oncology Florida Cancer Affiliates
Honoraria - Cardinal Health
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Novartis; OncoC4
 
Satish Shah
Stock and Other Ownership Interests - Flatiron Health (I)
 
Edward Arrowsmith
Employment - Tennessee Oncology
Stock and Other Ownership Interests - OneOncology
Consulting or Advisory Role - Flatiron Health
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calistoga Pharmaceuticals (Inst); Celgene (Inst); Cephalon (Inst); Chorus (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Eisai (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncogenex (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Sarah Cannon Research Institute (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Flatiron Health; OneOncology
Other Relationship - Sarah Cannon Research Institute (Inst)
 
Julio Antonio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Oncology Consultants; Roche; Spectrum Pharmaceuticals; Tersera; zogen
Honoraria - Agendia; Guardant Health; Tempus
Speakers' Bureau - Guardant Health; Tempus
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Genentech/Roche (Inst); Immatics (Inst); ImmunityBio (Inst); Immutep (Inst); IncMed (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Loxo/Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); NovoCure (Inst); Sermonix Pharmaceuticals (Inst); Tersera (Inst); Thrive Earlier Detection Corp (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Guardant Health; Tempus
 
Rohit Joshi
Honoraria - Bristol-Myers Squibb; Ipsen; Merck Sharp & Dohme; Pfizer; Pfizer/EMD Serono; Roche
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Roche
Speakers' Bureau - Gilead Sciences
 
Aiwu Ruth He
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Genentech/Roche
Speakers' Bureau - AstraZeneca; bms; Eisai
Research Funding - AstraZeneca; Genentech; Merck
 
Adriana Milillo
Employment - Memorial healthcare system
Research Funding - OncoC4
 
John Turner Hamm
Consulting or Advisory Role - Meda Pharmaceuticals
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); BrightPath Biotheraputics (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dana-Farber Cancer Institute (Inst); Deciphera (Inst); EMD Serono (Inst); EpicentRx (Inst); Exact Sciences (Inst); Five Prime Therapeutics (Inst); G1 Therapeutics (Inst); GBG Forschungs (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Halozyme (Inst); Immunicum (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Moffitt (Inst); National Surgical Adjuvant Breast and Bowel Project (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Pronova (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); SWOG (Inst)
 
Mark Gregory Goldstein
Stock and Other Ownership Interests - Cardinal Health; Guardant Health
Consulting or Advisory Role - Tempus
Research Funding - Pfizer
(OPTIONAL) Uncompensated Relationships - Thor Pharmaceuticals
 
Zihai Li
Stock and Other Ownership Interests - Agenus (I); yuMed
Honoraria - Alphamab; Heat Biologics; Henlius
Consulting or Advisory Role - Abbvie; Alphamab; HANCHORBIO; Heat Biologics; Henlius; Ikonisys
Research Funding - Bristol-Myers Squibb; Heat Biologics
Patents, Royalties, Other Intellectual Property - Have a patent on HSP vaccine technology that was license to Agenus
 
Yang Liu
Employment - OncoC4
Leadership - OncoC4
Stock and Other Ownership Interests - OncoC4
Patents, Royalties, Other Intellectual Property - Patent on ONC-392
 
Pan Zheng
Employment - OncoC4
Leadership - OncoC4
Stock and Other Ownership Interests - OncoC4
Patents, Royalties, Other Intellectual Property - Patent on ONC-392, a new next generation anti-CTLA-4 antibody.
 
Tianhong Li
Honoraria - Tempus
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Jounce Therapeutics (Inst); LabyRx Immuno-Oncology (Inst); Lung Cancer Mutation Consortium (Inst); Merck (Inst); Novartis (Inst); Nvigen (Inst); OncoImmune/OncoC4 (Inst); Pfizer (Inst); RasCal (Inst); Tempus (Inst)